Saxenda (liraglutide) is an FDA-approved GLP-1 receptor agonist for chronic weight management for adults with a BMI greater than or equal to 30 (obese) or 27 (overweight with comorbidities) and for pediatric patients (12+ years) with high BMI. It is used alongside a reduced-calorie diet and physical activity.
The FDA approved Saxenda after Phase III trials with over 5,000 in 56 weeks. Participants achieved greater than or equal to 5% and 10% weight loss compared to placebo. They received 3 mg doses alongside diet and exercise counseling. Serious side effects included pancreatitis, gallbladder disease, renal issues, and suicidal thoughts.
Using Saxenda involves an injectable pen, which may seem complex at first. However, understanding the dosing and administration process is essential for achieving optimal results. This guide offers clear, step-by-step Saxenda dosing instructions to help you use the medication effectively and with confidence.
Saxenda Dosage Forms
Saxenda is available as a 6 mg/mL solution in a 3 mL pre-filled pen designed for your single use. The pen allows you to adjust the dose, delivering the following amounts:
-
-
-
-
-
-
-
-
-
-
-
- 0.6 mg
- 1.2 mg
- 1.8 mg
- 2.4 mg
- 3 mg
-
-
-
-
-
-
-
-
-
-

Saxenda Dosing Chart
Here’s your Saxenda dosing chart, designed to guide you through a once-daily injection schedule:
| Week | Dose |
|---|---|
| Week 1 | 0.6 mg/day |
| Week 2 | 1.2 mg/day |
| Week 3 | 1.8 mg/day |
| Week 4 | 2.4 mg/day |
| Week 5 | 3 mg/day |
Saxenda Dosing Guide
Here’s a helpful Saxenda dosing guide to follow, whether you’re an adult or a pediatric patient:
Saxenda Dosing Guide for Adult Patients
-
- If you find that you can’t tolerate the 3 mg dose, it’s important to contact your healthcare provider before adjusting your dose or changing your treatment plan.
-
- If an increased dose isn’t well tolerated during escalation, you should consider extending the titration period by about one more week.
-
- Your weight should be reassessed after 16 weeks on Saxenda. If you’ve lost less than 4% of your starting weight, don’t stop treatment just yet, as discontinuing early could reduce your chances of long-term weight loss success.
-
- If you experience severe abdominal pain or serious allergic reactions, such as swelling or trouble breathing, you should stop using Saxenda immediately.
-
- For adult patients with type 2 diabetes, monitor your blood glucose levels before starting Saxenda and throughout your treatment.
Saxenda Dosing Guide for Pediatric Patients
-
- If you find that the 3 mg dose isn’t well tolerated, your dose may be adjusted to 2.4 mg daily.
-
- During dose escalation, if you experience any issues with an increased dose, the dose can be reduced back to the previous level for up to 8 weeks. In pediatric patients, dose escalation can take up to 8 weeks.
-
- Your BMI should be reassessed after 12 weeks on the maintenance dose. If you haven’t seen at least a 1% reduction from your starting point, Saxenda should be discontinued, as continuing treatment is unlikely to result in meaningful or sustainable weight loss.
Final Insights
Saxenda can be a powerful tool for your weight loss journey when paired with a healthy diet and regular exercise. In order to gradually increase the drug’s effectiveness and minimize the side effects, you should follow the Saxenda dosing instructions carefully. Also, tracking your progress such as your body weight is highly recommended. If you ever have questions or experience any challenges with the medication, reach out to your healthcare provider for personalized guidance and support.
Frequently Asked Questions
Related Articles
Sources
U.S. Food and Drug Administration. (2023). Saxenda (liraglutide) injection, for subcutaneous use: Labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf
Saxenda. (n.d.). About Saxenda: Dosing schedule. https://www.saxenda.com/about-saxenda/dosing-schedule.html
NovoMedlink. (n.d.). Saxenda dosing and administration. https://www.novomedlink.com/obesity/products/treatments/saxenda/dosing-administration/saxenda-dosing.html#
Mehta, A., Marso, S. P., & Neeland, I. J. (2016). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3–14. https://doi.org/10.1002/osp4.84
National Library of Medicine. (2019). Efficacy of the glucagon-like peptide-1 receptor agonist liraglutide for weight loss in patients with obesity: A systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/31203802/
Puhl, R. (2019). Obesity: A comprehensive treatment approach for adults. Obesity, 28(1), 44-51. https://onlinelibrary.wiley.com/doi/10.1002/oby.22462
Ozempic. (n.d.). Prescribing information. https://www.ozempic.com/prescribing-information.html
U.S. Food and Drug Administration. (2017). Saxenda (liraglutide) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
National Center for Biotechnology Information. (n.d.). Liraglutide (Subcutaneous Route). In Bookshelf (NBK594336). U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK594336/#
Saxenda. (n.d.). Support and resources: FAQs. https://www.saxenda.com/support-and-resources/faqs.html#
Baron, A. (2023). Generic weight loss drugs represent a new frontier in obesity treatment. Barron’s. https://www.barrons.com/articles/generic-weight-loss-drugs-e5a1754c
Teva Pharmaceutical Industries Ltd. (2024, June 13). Teva announces launch of authorized generic of Victoza® (liraglutide injection) 1.8mg in the United States. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Announces-Launch-of-Authorized-Generic-of-Victoza-liraglutide-injection-1.8mg-in-the-United-States/default.aspx
Saxenda. (n.d.). FAQs. https://www.saxenda.com/support-and-resources/faqs.html
Saxenda. (n.d.). Dosing schedule. https://www.saxenda.com/about-saxenda/dosing-schedule.html
Clinical Trials Arena. (n.d.). Saxenda (liraglutide) for obesity. Retrieved November 22, 2024, from https://www.clinicaltrialsarena.com/projects/saxenda-liraglutide-obesity/?cf-view
National Heart, Lung, and Blood Institute. (n.d.). Body mass index (BMI). Retrieved November 22, 2024, from https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi-m.htm
Saxenda. (2022). Saxenda patient brochure. Retrieved November 22, 2024, from https://www.saxenda.com/content/dam/obesity/saxenda/pdfs/US22SX00086_SAX_Patient_Brochure_Digital_V4.pdf




